# James P. Allison

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/james-p-allison/

## Facts

| Field | Value |
| --- | --- |
| Citations | 121,679 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 158 |
| i10-index | 433 |
| OpenAlex ID | https://openalex.org/A5047117233 |
| ORCID iD | https://orcid.org/0000-0001-8980-5697 |
| Works | 1,234 |

## Researcher papers

- [Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma](https://scholariq.org/papers/cancer-regression-and-autoimmunity-induced-by-cytotoxic-t-lymphocyte-associated/)
- [Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade](https://scholariq.org/papers/distinct-cellular-mechanisms-underlie-anti-ctla-4-and-anti-pd-1-checkpoint/)
- [Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis](https://scholariq.org/papers/epithelial-to-mesenchymal-transition-induces-cell-cycle-arrest-and-parenchymal/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma](https://scholariq.org/papers/neoadjuvant-immune-checkpoint-blockade-in-high-risk-resectable-melanoma/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention](https://scholariq.org/papers/a-genetic-mouse-model-recapitulates-immune-checkpoint-inhibitor-associated/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.